Cited in boardrooms, legal proceedings & government briefings since 2017
The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of entry has been complicated by the historic scheduling of cannabis as a schedule 1 narcotic.
Cited in boardrooms, legal proceedings & government briefings since 2017. Our figures are built to be defended — sourced, modelled and signed off by PP’s analysts.
Trusted by teams at
The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of entry has been complicated by the historic scheduling of cannabis as a schedule 1 narcotic. It combines PP’s proprietary market sizing with regulatory analysis, giving investors and corporates a single, citable reference — delivered digitally, licensed for internal use, and backed by the analysts who built the numbers.
75+
pages of analysis
2019
published
Investors & analysts
Defensible sizing and forecasts to underwrite the thesis.
Corporate strategy & FMCG
Opportunity sizing and entry routes across key markets.
